🇺🇸 FDA
Patent

US 10485829

Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

granted A61KA61K35/12A61P

Quick answer

US patent 10485829 (Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells) held by Astellas Institute for Regenerative Medicine expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Astellas Institute for Regenerative Medicine
Grant date
Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K35/12, A61P, A61P27/02